How should insulin therapy be selected for a 62‑year‑old man with uncontrolled type 2 diabetes and an infected ankle ulcer when he is admitted (a) to a private hospital with no budget constraints, and (b) to a government hospital with limited resources?

Insulin Selection for Hospitalized Patient with Type 2 Diabetes and Infected Ankle Ulcer

Private Hospital (No Budget Constraints)

Use a basal-bolus insulin regimen with long-acting basal insulin analogs (glargine or degludec) plus rapid-acting prandial insulin analogs (lispro, aspart, or glulisine) with correction doses. 1

Rationale and Implementation:

• Basal insulin component: Initiate long-acting insulin analog (glargine U-100 or degludec) at 0.1-0.25 units/kg/day for patients new to insulin, or 0.4-0.5 units/kg/day for insulin-experienced obese patients 1. Long-acting analogs provide superior hypoglycemia reduction compared to NPH insulin, particularly important given the infection and wound healing requirements 1.

• Prandial insulin component: Add rapid-acting insulin analog (lispro, aspart, or glulisine) before each meal, starting with 4 units or 10% of basal dose at the largest meal 1. These analogs have pharmacokinetics that better match physiologic meal-related insulin needs 2.

• Correction doses: Administer rapid-acting analog for pre-meal glucose >140 mg/dL, using a structured correction scale rather than sliding-scale monotherapy 1.

• Glucose monitoring: Perform point-of-care testing immediately before each meal and at bedtime 1. Target glucose 140-180 mg/dL to optimize wound healing while minimizing hypoglycemia risk 1, 3.

• Avoid sliding-scale insulin alone: This reactive approach is strongly discouraged as it treats hyperglycemia after occurrence rather than preventing it, leading to poor glycemic control and increased complications 1.

Key Advantages in This Setting:

• Modern insulin analogs reduce severe hypoglycemia risk by 35-63% compared to human insulins 1, critical for a patient with infection requiring stable glucose control for wound healing 1.
• Flexible dosing accommodates variable oral intake common during acute illness 1.
• Superior glycemic control reduces hospital complications and improves surgical outcomes 1.

---

Government Hospital (Limited Resources)

Use human NPH insulin twice daily plus human regular insulin before meals, or alternatively, premixed human insulin 70/30 twice daily if the basal-bolus approach is not feasible. 1

Rationale and Implementation:

• Primary regimen - NPH/Regular basal-bolus: NPH insulin 0.1-0.25 units/kg divided into two doses (morning and bedtime), plus regular human insulin 4 units before each meal 1. Human insulin vials cost approximately $25 each, making this the most cost-effective option 1.

• Alternative regimen - Premixed 70/30: If basal-bolus is too complex for available nursing resources, use premixed human insulin 70/30 twice daily (before breakfast and dinner) 1. However, recognize this carries higher hypoglycemia risk in hospitalized patients 1.

• Timing considerations: Regular insulin must be administered 30-45 minutes before meals 1. If meal timing is unpredictable due to procedures or facility constraints, consider giving regular insulin immediately after meals with dose adjusted to food consumed 1.

• Glucose monitoring: Test before meals and at bedtime, minimum 4 times daily 1. Target 140-180 mg/dL 1, 3.

• Correction doses: Use regular human insulin for correction, though recognize its slower onset compared to analogs 1.

Critical Considerations for Resource-Limited Settings:

• Human insulin is WHO-recommended: The World Health Organization specifically recommends human insulin (both regular and NPH) as first-line therapy in low-resource settings, reserving analogs only for patients with frequent severe hypoglycemia 1.

• Cost justification: Human insulin provides adequate glycemic control at a fraction of the cost of analogs 1. The modest benefits of analogs (primarily reduced hypoglycemia) do not justify universal use when resources are constrained 1.

• Efficacy: Meta-analyses show no clinically meaningful difference in HbA1c reduction between human insulin and analogs in type 2 diabetes 1.

• Avoid premixed analogs: These are significantly more expensive ($180-424 per vial) without proven superiority over human premixed formulations 1.

Common Pitfalls to Avoid:

• Never use sliding-scale insulin alone in either setting—it increases complications and fails to provide basal coverage 1.
• Do not continue metformin if the patient has sepsis, hypoxia, or renal impairment (eGFR <30 mL/min) due to lactic acidosis risk 1.
• Discontinue sulfonylureas upon admission to avoid unpredictable hypoglycemia during acute illness 1.
• Monitor for hypoglycemia more vigilantly with NPH compared to long-acting analogs, particularly overnight and pre-lunch 1.
• Ensure adequate nutrition timing with regular insulin to prevent hypoglycemia from the 30-45 minute pre-meal dosing requirement 1.